Replimune(REPL) - 2026 Q2 - Quarterly Results

Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Woburn, MA, November 6, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update. The Company announced on October 20, 2025, that the U.S. Food and Drug Administration (FDA) has accepted the BLA r ...